KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Jazz Pharmaceuticals (JAZZ) Invested Capital: 2009-2025

Historic Invested Capital for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Sep 2025 value amounting to $9.3 billion.

  • Jazz Pharmaceuticals' Invested Capital fell 9.36% to $9.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 billion, marking a year-over-year decrease of 9.36%. This contributed to the annual value of $10.2 billion for FY2024, which is 7.96% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Invested Capital stood at $9.3 billion, which was up 2.75% from $9.1 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Invested Capital registered a high of $10.9 billion during Q2 2021, and its lowest value of $5.9 billion during Q1 2021.
  • Moreover, its 3-year median value for Invested Capital was $9.4 billion (2024), whereas its average is $9.5 billion.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Invested Capital soared by 107.24% in 2021, and later dropped by 17.08% in 2022.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Invested Capital stood at $10.0 billion in 2021, then dropped by 12.03% to $8.8 billion in 2022, then increased by 7.26% to $9.4 billion in 2023, then climbed by 7.96% to $10.2 billion in 2024, then declined by 9.36% to $9.3 billion in 2025.
  • Its last three reported values are $9.3 billion in Q3 2025, $9.1 billion for Q2 2025, and $9.5 billion during Q1 2025.